Minerva Neurosciences plunges after FDA refuses to accept schizophrenia drug filing

Minerva Neurosciences

17/10/2022 14:20

** Shares of drug developer Minerva Neurosciences Inc
 NERV.O  plummet 68.4% to $4.25 premarket
    ** Set for worst day since May 2020 if losses hold; among
top pct. losers across U.S. exchanges
    ** NERV says U.S. FDA has sent it a "refusal to file"
letter, refusing to accept its application seeking approval for
its experimental therapy, roluperidone, targeting negative
symptoms of schizophrenia   urn:newsml:reuters.com:*:nGNX4V1TS8
    ** Says it plans to request a meeting with the FDA to
discuss further
    ** NERV had submitted the application in August  urn:newsml:reuters.com:*:nL4N2ZY2PD
    ** Stock had more than doubled YTD through last close
 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))